Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

First Posted Date
2023-09-28
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
3680
Registration Number
NCT06058377
Locations
🇺🇸

Banner University Medical Center - Tucson, Tucson, Arizona, United States

🇺🇸

University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

🇺🇸

Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States

and more 406 locations

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

First Posted Date
2023-09-26
Last Posted Date
2023-09-26
Lead Sponsor
Biocity Biopharmaceutics Co., Ltd.
Target Recruit Count
112
Registration Number
NCT06055348

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

First Posted Date
2023-09-25
Last Posted Date
2024-02-07
Lead Sponsor
Dan Zandberg
Target Recruit Count
15
Registration Number
NCT06052839
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

First Posted Date
2023-09-21
Last Posted Date
2024-12-11
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
168
Registration Number
NCT06043427
Locations
🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

🇨🇦

BCCA - Vancouver, Vancouver, British Columbia, Canada

🇨🇦

CancerCare Manitoba, Winnipeg, Manitoba, Canada

and more 12 locations

Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

First Posted Date
2023-09-21
Last Posted Date
2024-10-16
Lead Sponsor
Neonc Technologies, Inc.
Target Recruit Count
134
Registration Number
NCT06047379
Locations
🇺🇸

Precision NextGen Oncology, Beverly Hills, California, United States

🇺🇸

Northwest Medical Specialties, Tacoma, Washington, United States

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

First Posted Date
2023-09-15
Last Posted Date
2024-08-02
Lead Sponsor
Toray Industries, Inc
Target Recruit Count
146
Registration Number
NCT06038578
Locations
🇺🇸

Texas Oncology-Sammons Cancer Center, Dallas, Texas, United States

🇰🇷

ASAN Medical Center, Seoul, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

and more 8 locations

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

First Posted Date
2023-09-05
Last Posted Date
2024-07-23
Lead Sponsor
Yonsei University
Target Recruit Count
198
Registration Number
NCT06023862
Locations
🇰🇷

Bundang Seoul National University Hospital, Seongnam-si, Korea, Republic of

🇰🇷

Severance Hospital, Yonsei Health System, Seoul, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

and more 5 locations

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

First Posted Date
2023-08-30
Last Posted Date
2024-11-26
Lead Sponsor
DualityBio Inc.
Target Recruit Count
532
Registration Number
NCT06018337
Locations
🇺🇸

Research Site 1141-0, Tucson, Arizona, United States

🇺🇸

Research Site 1114-0, Fullerton, California, United States

🇺🇸

Research Site 1107-0, Los Angeles, California, United States

and more 182 locations

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

First Posted Date
2023-08-22
Last Posted Date
2024-05-17
Lead Sponsor
University of Chicago
Target Recruit Count
36
Registration Number
NCT06005324
Locations
🇺🇸

University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

First Posted Date
2023-08-14
Last Posted Date
2023-08-14
Lead Sponsor
Akeso
Target Recruit Count
642
Registration Number
NCT05990127
Locations
🇨🇳

The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

🇨🇳

Cancer hospital, Chinese academy of medical sciences and Peking union medical college, Beijing, Beijing, China

and more 59 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy